Answers are grounded in this paper and cite their sources.
At the end of 2005, six European countries had implemented public immunization campaigns with serogroup C conjugate vaccines, and all had experienced substantial declines in the incidence of serogroup C disease. A quadrivalent ACWY meningococcal vaccine is in use in the USA, but serogroup A is extremely rare in Europe and serogroups Y and W135 are infrequent causes of disease. This paper outlines recommendations on the use of conjugate vaccines in Europe based on the experience with meningococcal C conjugate (MCC) vaccines so far.
No takes yet. Share an insight, caveat, or question.
Trotter et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: